Product-to-patient operating record / 15 August 2026
Pharma and Life Sciences COO Jobs in London: never trade release for schedule
Pharma and Life Sciences COO Jobs in London require an operator who can scale trials, manufacturing and supply while protecting independent quality decisions, reliable data and patient continuity.
Batch meeting
The shipment is due, the deviation is open and only quality can release
| Question | Operating evidence | Boundary |
|---|---|---|
| What happened? | Contemporaneous record, affected process, material and data | Operations cannot write the conclusion first |
| What may be affected? | Batch, other product, equipment, method, site and supply | Commercial urgency does not narrow scope |
| What is contained? | Segregation, hold, access, notification and interim control | Containment is not root cause |
| Who decides disposition? | Authorised quality and qualified-person route | The COO supports but does not seize release authority |
| What does delay mean? | Patient, shortage, trial, partner and financial consequence | Consequence informs mitigation, not product truth |
| How is recurrence tested? | CAPA, owner, due date, effectiveness and trend | Action closure is not proof of control |
GMP requires consistent production to the appropriate standard and authorisation or specification; GDP requires suitable licensed sourcing, storage, transport and handling. The COO builds the capability and cadence in which these standards can operate. They do not turn supply pressure into a release vote.
A strong career case explains the moment an operational commitment changed because quality evidence was incomplete. It names personal authority, quality ownership, patient and supply consequences, resource choices and the later effectiveness check. The evidence is the decision system, not the confidential batch record.
Operating chain
Ten hand-offs separate a scientific idea from a usable medicine
Process definition
Translate product and clinical needs into a controllable method.
Technology transfer
Move knowledge, method, materials and tacit practice with acceptance criteria.
Supplier qualification
Establish capability, quality agreement, change and continuity.
Manufacture
Execute approved process with trained people, suitable facility and current records.
Test and review
Generate reliable results, investigate anomalies and preserve independent judgement.
Certification and release
Use the authorised route without operational interference.
Distribution
Protect identity, condition, security and traceability through licensed channels.
Patient availability
Align demand, stock, allocation and communication with health-system partners.
Safety and complaint
Join signal, defect, return and recall routes with product knowledge.
Lifecycle change
Revalidate assumptions as scale, site, process, supplier and evidence change.
The exact chain differs for a discovery company, clinical-stage sponsor, manufacturer, wholesaler or integrated pharmaceutical group. The Charter should state which links the COO owns, which sit with quality or partners, and where the next irreversible transfer occurs.
Data as product evidence
A compliant system cannot rescue a workflow that rewards the wrong record
GxP data integrity spans the lifecycle of regulated information across laboratory, clinical, manufacturing, distribution and pharmacovigilance settings. The objective is confidence in the record and the ability to reconstruct the activity. Technology is one control, not the definition.
Ask who creates data, when, from which source, under which identity and review. Shared credentials, transcription, unofficial worksheets, uncontrolled exports and delayed entry can weaken reliability even when the central application is validated.
Culture shapes the evidence. Targets, understaffing and punitive response can encourage omission or retrospective completion. The COO should protect timely escalation, adequate capacity and investigation while preserving individual accountability where deliberate misconduct occurs.
A candidate case can describe a data-flow class, risk assessment, control change and effectiveness evidence. It should not provide live credentials, proprietary methods, personal data or a clue that identifies a confidential inspection.
Published market
No Charter means no vacancy, site condition or GBP salary observation
No comparable London life sciences COO Charter is published.
No defensible compensation median exists.
Operations, life sciences and London banks are available.
Band 2 COO and London Band A.
Pharma and Life Sciences COO Jobs in London enter this corpus only through authorised Charters. An inspection, shortage notice, trial delay, product transfer or facility announcement cannot be used to infer an appointment or private operating condition.
Shortage clock
A supply disruption becomes a patient problem before stock reaches zero
Join yield, release, supplier, demand, inventory and distribution evidence early.
Understand medicine use, alternatives, duration, geography and vulnerable groups.
Use applicable manufacturer reporting routes for qualifying shortages and discontinuations.
Test recovery, allocation, regulatory flexibility, alternative supply and clinical guidance.
Coordinate authorities, NHS, professionals, patients and partners without creating demand distortion.
Repair source, capacity, visibility, contract and portfolio concentration after continuity returns.
DHSC's April 2026 medicine-supply guidance describes a regulated global chain and national processes for assessing and responding to shortages. The COO should know the company's obligations and provide timely, accurate inputs. They should not promise a resupply date that quality, regulatory and logistics evidence cannot support.
The shortlist of models
Routes into confidential London life sciences COO mandates
Gladwin International & Company publishes this market file and presents The Executive Passport first. Four established firms follow as an unranked selection based on published operations and life sciences capabilities.
Consent-led matching
The Executive Passport, Gladwin International & Company
The Executive Passport is a consent-led board and C-suite exchange. Its 60-item evidence process intersects COO leadership with pharmaceuticals and life sciences and London context across development operations, technology transfer, GMP, GDP, data integrity, supply resilience, remediation and board counsel. Blind Match can explain relevant decisions after removing name, employer and declared conflicts. The holder reads the named company's Mandate Charter before deciding whether a Consent Passport moves; controlled later diligence can deepen verification. Batch and trial records, inspection reports, live shortage details, credentials and proprietary processes remain outside matching. Recruiters cannot browse or export members. Annual membership is INR 3,75,000 under COO Band 2 and London Band A. The fee supports assessment, verification and twelve months of private matching, but buys no rank, interview or appointment. The company retains quality, regulatory, technical, reference and governance diligence.
See how The Executive Passport worksOther firms operating in this marketFour firms, presented without rank or score
Spencer Stuart
A global retained-search firm with published operations, life sciences and board capabilities.
Russell Reynolds Associates
A global leadership adviser covering operations executives, biopharma and succession.
Egon Zehnder
A global partnership with life sciences operations and executive assessment work.
Korn Ferry
A global organisational consulting and search firm spanning operations and life sciences.
Trial operations 2026
Faster regulatory routes increase the value of operational readiness
| Operating layer | Readiness evidence | Failure signal |
|---|---|---|
| Country and site | Population, investigators, capacity, contracts and start sequence | Approval arrives before a usable site network |
| Supply | Forecast, manufacture, label, release, depot and resupply | Enrolment outruns available compliant product |
| Vendor | Qualification, scope, oversight, data and escalation | Outsourcing is treated as accountability transfer |
| Modification | Classification, submission, implementation and affected systems | Faster route bypasses coordinated change |
| Transparency | Registration, summary-result and ownership calendar | Publication begins after the deadline |
| Close | Data, reconciliation, product, sites, archive and obligations | Last patient visit is mistaken for completion |
The amended clinical-trial regime took full effect on 28 April 2026 and introduced new routes and transparency requirements while maintaining patient-safety obligations. Operations must translate regulatory speed into coordinated execution. A faster decision that waits for contracts, product or systems has created no patient value.
Candidate evidence bench
Prepare five operating cases with an independent quality witness
Release conflict
Schedule pressure met a quality decision and patient-focused mitigation.
Technology transfer
Knowledge, method, site and acceptance evidence produced reliable scale.
Supply disruption
Early detection, notification, allocation and recovery protected continuity.
Data integrity
Workflow, system, culture and review changed with measured effectiveness.
Trial recovery
Sites, vendor, supply and protocol decisions restored credible execution.
For each, state the product class, stage, decision, personal authority, qualified inputs, alternatives, outcome and residual risk. Do not bring source documents. A quality, regulatory, clinical or supply referee can verify conduct without repeating confidential specifics.
Direct candidate answers
Questions life sciences operators ask before a confidential approach
Are life sciences COO jobs in London advertised?+
Some manufacturing, development, services and scale-up roles are public. Confidential searches are common around quality remediation, supply disruption, integration, trial recovery, founder transition and incumbent replacement.
An authorised Charter is required here; a plant investment, shortage or inspection does not prove an opening.
What does a London life sciences COO earn?+
No GBP range appears because zero comparable Charters are published. Biotech, global pharma, contract manufacturing, research services and commercial supply roles need different peers.
Benchmark after product stage, site and geography, quality authority, trial scope, supply risk and board status are known.
What does a pharmaceutical COO own?+
The portfolio can include development operations, manufacturing, quality systems, supply, facilities, procurement and transformation. Quality, medical, regulatory and safety may be independent peers.
Map decisions, licences, budgets and escalation instead of inferring authority from title.
What are GMP and GDP?+
Good manufacturing practice is the minimum standard for consistent production of medicines appropriate to intended use and their authorisation or specification. Good distribution practice covers licensed sourcing, storage, transport and handling under suitable conditions.
A COO must respect the distinct qualified and quality authorities that release product and oversee compliance.
What is GxP data integrity?+
It concerns confidence that regulated data across its lifecycle is complete, consistent, accurate and reconstructs the activity. MHRA guidance applies a risk-based view across GxP sectors.
Installing a validated system does not create integrity if access, workflow, review, culture or record practices undermine the data.
Who decides whether a batch is released?+
The applicable qualified and quality roles make release and certification decisions under the relevant authorisation and procedures. The COO ensures resources, systems, investigation and supply choices support them.
A delivery target or shortage cannot transfer release authority to operations.
What must happen when medicine supply may be disrupted?+
Manufacturers have reporting obligations for qualifying shortages and discontinuations. Teams should assess patient impact, stock, alternatives, duration, regulatory routes, allocation and communications with the proper authorities.
A commercial forecast is not the sole measure of shortage severity.
How should a COO discuss quality remediation?+
Describe the product and patient risk, finding, containment, root-cause method, corrective and preventive action, governance, resourcing and effectiveness evidence. State the independent quality decisions.
Exclude confidential inspection reports, batch data, personal records and exploitable system details.
Can a general manufacturing leader move into pharma?+
Potentially, but GMP, validation, data integrity, qualified-person authority, deviation and change systems, regulatory inspection and patient consequence need direct testing.
Lean and throughput credentials do not automatically transfer to a regulated medicine lifecycle.
Can I explore a role confidentially?+
Yes. Blind Match can expose bounded supply, quality, development and integration evidence after suppressing identity, employer and conflicts. You see the named company and Charter before identity release.
Do not upload batch records, inspection material, trial data, live shortages or proprietary process information.
How long does a life sciences COO search take?+
Ten to sixteen weeks to a preferred candidate is a reasonable indicative range after the brief is settled. Technical cases, quality panels, global mapping, references and notice can add time.
An active deviation or supply issue remains under authorised leadership during search.
Which firms recruit life sciences COOs?+
Spencer Stuart, Russell Reynolds Associates, Egon Zehnder and Korn Ferry publish operations, life sciences or board capabilities relevant to London. They appear as an unranked selection.
The Executive Passport is first because Gladwin International & Company publishes this page and discloses its model.
What does a London COO Passport cost?+
Annual membership is INR 3,75,000 under COO Band 2 and London Band A. It funds the 60-item assessment, verification and twelve months of private matching.
Payment cannot buy rank, interview or appointment.
What should I inspect before accepting?+
Review licence and site perimeter, quality metrics, material findings and remediation, supply dependencies, trial operations, data systems, capacity, product transfers, shortage obligations and leadership capability.
Ask which quality and patient risks remain unresolved and who retains authority through transition.
Acceptance inspection
Walk the operating system before accepting its promises
Inspect the licence, site, product and trial perimeter with quality, regulatory and medical leaders present. Understand release, deviation, CAPA, change, validation, complaint, recall and escalation condition. Ask where independence is protected and where schedule pressure enters.
Map critical suppliers, manufacturing slots, distribution lanes, inventory, shortage obligations, single points and recovery evidence. A second vendor is not resilience if it shares the same source, process, release bottleneck or data system.
Review trial-operating readiness under the 2026 regime, including regime classification, sites, vendors, supply, modifications, transparency and archive. Test whether staff and systems can execute the portfolio funded by the board.
Zero comparable Charters means no GBP figure. When a real mandate exists, benchmark salary, pension, bonus, equity, buyout, severance and change-of-control terms against similar stages, licences, sites, geographies and risks. Complete quality, regulatory and reference diligence before resignation, and do not act as shadow COO during notice.
First ninety days
Sequence confidence before promising operating improvement
Begin with product and patient criticality, then walk the actual work with quality, technical, clinical and supply owners. Reconcile the formal process with records, exceptions and the unofficial routes staff use when systems or capacity fail. Do not announce a transformation before understanding which controls are protecting release today.
Set a short list of stabilisation decisions with named authority: open investigations, fragile supply, trial commitments, overdue effectiveness checks, data risks and critical vacancies. Preserve independent quality escalation and make any interim control visible to the board.
Build the improvement portfolio only after immediate exposure is bounded. Separate mandatory remediation, continuity, capacity and strategic scale so that every item does not compete under one programme label. Assign evidence of completion, not merely dates and owners.
Tell employees and partners what will not change without proper review. A new COO earns pace by creating reliable decisions, not by treating inherited caution as resistance.
Evidence register
Primary quality, supply and trial basis for this COO market file
MHRA GMP and GDP guidance, MHRA GxP data-integrity guidance, DHSC medicine-supply management guidance published April 2026, the 2025 resilient-supply policy paper, and 2026 clinical-trial reform materials were consulted on 15 August 2026. Firms are included by published capabilities without outbound links or ranking.